Virtual Library

Start Your Search

Xing Yasi



Author of

  • +

    P2.01 - Advanced NSCLC (ID 159)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.01-50 - CD 146 a Potential Therapeutic Target for Lung Cancer (ID 1434)

      10:15 - 18:15  |  Author(s): Xing Yasi

      • Abstract

      Background

      Non-small-cell lung cancer (NSCLC) patients often exhibit lymphopenia, which has been associated with poor clinical outcomes. However, the mechanisms that lead to lymphopenia have not been fully established. CD 146 is an important glycoprotein found on the integral membrane of the cells. Its ectodomain contains five immunoglobulin-like domains and its cytoplasmic tail contains potential protein kinase C recognition sites and PDZ binding sites indicating possible involvements in cell signaling

      Method

      Blood was collected from lung cancer patients and from healthy subjects. The frequency of CD146 cells and the expression of CD 4, CD45, CD 127, CD 25 were determined by flow cytometry. Lymphocytes apoptosis was determined by 7-amino-actinomycin D/Annexin V-APC staining.

      Result

      The percentage of CD 146 was significantly higher in patients than in controls.

      CD 146 expression in whole-blood samples was higher in NSCLC patients than in controlsola 1.jpgola 2.jpg

      Conclusion

      Increased CD 146 expression on the blood of lung cancer patients may be associated with the underlying mechanisms leading to lymphopenia in NSCLC patients